Intravenous Lidocaine for Opioid-Resistant Pain Control in Metastatic Breast Cancer

Article Information

Elizabeth Higgins MD*, Ellen Nielsen MD

The Medical University of South Carolina’s, Charleston, SC 29425, United States

*Corresponding Author: Dr. Elizabeth Higgins, The Medical University of South Carolina’s, Charleston, SC 29425, United States

Received: 21 December 2020; Accepted: 11 January 2021; Published: 18 January 2021

Citation: Elizabeth Higgins, Ellen Nielsen. Intravenous Lidocaine for Opioid-Resistant Pain Control in Metastatic Breast Cancer. Archives of Clinical and Medical Case Reports 5 (2021): 151-155.

View / Download Pdf Share at Facebook

Abstract

A fifty-one-year-old woman presented with pain related to metastatic breast cancer. The palliative care team was consulted for acute pain management intervention. At home, she was taking methadone for pain control. However, shooting pains down her legs had progressed to an unmanageable level, to the point where she was confided to bed. She was admitted to the hospital and was started on a hydromorphone PCA without complete pain control. Intravenous lidocaine was trialed and significantly improved the patient’s pain and decreased the need for other opioid medications. After these results, she was started on a lidocaine drip without side effects noted.

Keywords

Cancer; Intravenous Lidocaine; Metastatic Breast Cancer

Cancer articles; Intravenous Lidocaine articles; Metastatic Breast Cancer articles

Cancer articles Cancer Research articles Cancer review articles Cancer PubMed articles Cancer PubMed Central articles Cancer 2023 articles Cancer 2024 articles Cancer Scopus articles Cancer impact factor journals Cancer Scopus journals Cancer PubMed journals Cancer medical journals Cancer free journals Cancer best journals Cancer top journals Cancer free medical journals Cancer famous journals Cancer Google Scholar indexed journals Intravenous Lidocaine articles Intravenous Lidocaine Research articles Intravenous Lidocaine review articles Intravenous Lidocaine PubMed articles Intravenous Lidocaine PubMed Central articles Intravenous Lidocaine 2023 articles Intravenous Lidocaine 2024 articles Intravenous Lidocaine Scopus articles Intravenous Lidocaine impact factor journals Intravenous Lidocaine Scopus journals Intravenous Lidocaine PubMed journals Intravenous Lidocaine medical journals Intravenous Lidocaine free journals Intravenous Lidocaine best journals Intravenous Lidocaine top journals Intravenous Lidocaine free medical journals Intravenous Lidocaine famous journals Intravenous Lidocaine Google Scholar indexed journals Metastatic Breast Cancer articles Metastatic Breast Cancer Research articles Metastatic Breast Cancer review articles Metastatic Breast Cancer PubMed articles Metastatic Breast Cancer PubMed Central articles Metastatic Breast Cancer 2023 articles Metastatic Breast Cancer 2024 articles Metastatic Breast Cancer Scopus articles Metastatic Breast Cancer impact factor journals Metastatic Breast Cancer Scopus journals Metastatic Breast Cancer PubMed journals Metastatic Breast Cancer medical journals Metastatic Breast Cancer free journals Metastatic Breast Cancer best journals Metastatic Breast Cancer top journals Metastatic Breast Cancer free medical journals Metastatic Breast Cancer famous journals Metastatic Breast Cancer Google Scholar indexed journals Wide-complex tachycardia articles Wide-complex tachycardia Research articles Wide-complex tachycardia review articles Wide-complex tachycardia PubMed articles Wide-complex tachycardia PubMed Central articles Wide-complex tachycardia 2023 articles Wide-complex tachycardia 2024 articles Wide-complex tachycardia Scopus articles Wide-complex tachycardia impact factor journals Wide-complex tachycardia Scopus journals Wide-complex tachycardia PubMed journals Wide-complex tachycardia medical journals Wide-complex tachycardia free journals Wide-complex tachycardia best journals Wide-complex tachycardia top journals Wide-complex tachycardia free medical journals Wide-complex tachycardia famous journals Wide-complex tachycardia Google Scholar indexed journals Lidocaine  articles Lidocaine  Research articles Lidocaine  review articles Lidocaine  PubMed articles Lidocaine  PubMed Central articles Lidocaine  2023 articles Lidocaine  2024 articles Lidocaine  Scopus articles Lidocaine  impact factor journals Lidocaine  Scopus journals Lidocaine  PubMed journals Lidocaine  medical journals Lidocaine  free journals Lidocaine  best journals Lidocaine  top journals Lidocaine  free medical journals Lidocaine  famous journals Lidocaine  Google Scholar indexed journals treatment articles treatment Research articles treatment review articles treatment PubMed articles treatment PubMed Central articles treatment 2023 articles treatment 2024 articles treatment Scopus articles treatment impact factor journals treatment Scopus journals treatment PubMed journals treatment medical journals treatment free journals treatment best journals treatment top journals treatment free medical journals treatment famous journals treatment Google Scholar indexed journals PEComas articles PEComas Research articles PEComas review articles PEComas PubMed articles PEComas PubMed Central articles PEComas 2023 articles PEComas 2024 articles PEComas Scopus articles PEComas impact factor journals PEComas Scopus journals PEComas PubMed journals PEComas medical journals PEComas free journals PEComas best journals PEComas top journals PEComas free medical journals PEComas famous journals PEComas Google Scholar indexed journals surgery articles surgery Research articles surgery review articles surgery PubMed articles surgery PubMed Central articles surgery 2023 articles surgery 2024 articles surgery Scopus articles surgery impact factor journals surgery Scopus journals surgery PubMed journals surgery medical journals surgery free journals surgery best journals surgery top journals surgery free medical journals surgery famous journals surgery Google Scholar indexed journals microphthalmia articles microphthalmia Research articles microphthalmia review articles microphthalmia PubMed articles microphthalmia PubMed Central articles microphthalmia 2023 articles microphthalmia 2024 articles microphthalmia Scopus articles microphthalmia impact factor journals microphthalmia Scopus journals microphthalmia PubMed journals microphthalmia medical journals microphthalmia free journals microphthalmia best journals microphthalmia top journals microphthalmia free medical journals microphthalmia famous journals microphthalmia Google Scholar indexed journals tomography articles tomography Research articles tomography review articles tomography PubMed articles tomography PubMed Central articles tomography 2023 articles tomography 2024 articles tomography Scopus articles tomography impact factor journals tomography Scopus journals tomography PubMed journals tomography medical journals tomography free journals tomography best journals tomography top journals tomography free medical journals tomography famous journals tomography Google Scholar indexed journals

Article Details

1. Background

Untreated pain is a distressing phenomenon for physicians, patients and society. It takes a toll on the economy, costing an estimated $560 - 635 billion annually in health care costs and lost productivity [1]. Managing pain is a challenge for many physicians and patients to find the right balance of benefits and risks. Currently opioids are the most commonly used analgesia for moderate to severe acute pain, however, this is not risk free [2]. Opioid use has been associated with increased post-operative complications including respiratory depression, nausea, vomiting and gastrointestinal slowing [2]. Additionally, there is a growing opioid addiction epidemic growing in this country. In general, there has been a growing trend in healthcare to find other mechanisms of pain relief. Moreover, when opioids fail to manage a patient’s pain, other options must be explored. One of these options is intravenous lidocaine, which has been shown to be effective in treating opioid-refractory cancer pain [2]. This treatment was reported for pain management as early as 1962 by Bartlett and Hutaserani, however there is still not much written on its efficacy or indications [3].

2. Case Presentation

A 51 year old female presented with metastatic estrogen-receptor positive, progesterone-receptor positive, HER-2 positive, pleomorphic lobular carcinoma of her left breast, diagnosed six months prior. An initial MRI found metastasis to the lumbar spine and a T12 compression fracture. She chose to explore alternative therapies for a short course, and then was treated with tamoxifen and leuprolide. However, her pain continued to worsen, compelling her to enroll in hospice for pain management. This included palliative radiation to the sacrum and thoracic spine, which provided temporary pain relief. After a short time though, she presented to our hospital for uncontrolled pain, concerning for progressive metastatic disease.

The pain was located in her lower back and was triggered by movement with shooting pains down both legs. No muscle weakness, changes in sensation, or focal neurologic deficits were present, but walking was impaired by pain. On physical exam, she was unable to lift her legs without shooting pain and spasms. Upper extremity strength was 4/5 and lower extremity strength was 3/5. The patient was in excruciating pain and rated it as a 201/10.

3. Treatment

Prior to hospitalization for pain control, she was taking 15 milligrams of methadone every 6 hours with hydromorphone (Dilaudid) as needed for breakthrough pain. She had tried 50 microgram/hour fentanyl patches in the past, but this was discontinued due to the cost. On presentation, she was started on a hydromorphone PCA, 25 mg of nortriptyline nightly, and 5 mg of baclofen three times a day. On day 2 of hospitalization, methadone was decreased to every 8 hours due to drowsiness. On day 3, she reported continued pain despite extensive courses of opioid pain medications. On exam, she was unable to get out of bed due to the shooting pains down her legs when moving them. At this time, IV lidocaine was proposed.

A trial of lidocaine was given to assess pain response. For this, 100 milligrams of IV lidocaine was administrated over a half hour. At baseline, she was unable to lift legs without shooting pain and spasms. She reported some decreased range of motion of upper extremities when lifting arms to head with rare shooting pain down neck. Upper extremity strength was 4/5 and lower extremity strength was 3/5. At 15 minutes, she was able to lift her legs while laying down without pain or muscle spasms. At 30 minutes, she reported a complete resolution of pain. She was able to sit up unassisted on the side of the bed, then stand and walk with the assistance of a walker. The patient’s overall pain was significantly improved and she rated it as a 2/10. She had full range of motion of upper extremities without pain. Upper extremity strength was 5/5 and lower extremity strength was 5/5. After the trial, her heart rate increased while standing to (96->142) but returned to baseline when she returned to bed (95). Blood pressure remained unchanged during the trial. No adverse effects were reported including no seizures, no changes in mental status, no nausea or vomiting.

4. Outcome and Follow-Up

Following the response to the trial, a lidocaine drip was started at 1 mg/kg/hr. Methadone was decreased to 15 milligrams twice daily. As the day when on she reported slight increase in pain and lidocaine drip was increased to 1.135 mg/kg/hr. She was transferred to a community hospital, with a plan to continue increasing lidocaine dose as necessary with a maximum of 2 mg/kg/hr. In the 48 hours prior to the lidocaine infusion, her total methadone dose was 90 mg with 81.23 mg of hydromorphone delivered via PCA. In the 48 hours following lidocaine initiation, opioid use significantly decreased. Total methadone given was 60 mg with 33.65 mg of hydromorphone delivered via PCA.

 

24-hour methadone dosage

24-hour hydromorphone PCA requirement

Relative to starting lidocaine drip (24 hr periods)

   

2 days before

45 mg

60.39 mg

1 day before

45 mg

20.84 mg

1 day after

30 mg

9.65 mg

2 days after

30 mg

24 mg

Table 1: Treatment of methadone and hydromorphone PCA dosage.

5. Discussion

Lidocaine modulates pain through its analgesic and anti-inflammatory effects [2]. It works on neuronal cell membranes to interrupt pain by blocking a voltage-gated sodium channel [4]. Lidocaine patches are a commonly used in long-term pain management treatment, however IV lidocaine is a much less used intervention [5]. Intravenous lidocaine has been suggested as a treatment for opioid resistant pain. It has been shown in studies to be effective at treating refractory cancer pain, complex regional pain syndrome, neuropathic pain syndromes, traumatic or post-herpetic peripheral nerve injury, and surgical pain [2,5]. A 1986 placebo-controlled study found IV lidocaine significantly improved chronic pain in 78% of participants, with effects lasting 2 hours to 25 days [6]. Lidocaine also has been shown to reduce opioid consumption [2]. A double-blind study by Terkawi et al. found a decrease in chronic post-surgical pain in breast cancer patients after IV lidocaine infusion [7]. A double-blind, randomized trial by Sharma et al. found increased analgesic effects up to 9 days after infusion in chancer pain patients [8].

Dosage for IV lidocaine has been studied as well. The dosage selected in this case was based off the MUSC Palliative guidelines for IV lidocaine use. Following this guide, an initial trial of 100 milligrams of IV lidocaine was administrated over a half hour was given as a predictor of effectiveness before starting the lidocaine drip. Following success of the trial, 1mg/kg/hr of lidocaine was started and increased as needed. Studies have found that 1.33–3 mg/kg/hour IV lidocaine dosage achieved goal plasma concentrations of 2–5 μg/mL [2].

Side effects of lidocaine treatment must also be considered. One study found one side effect reported in 52% of patients [2]. Side effects of IV lidocaine include dizziness, sedation, tinnitus, seizures and arrhythmias [4]. Other less serious side effects include, metallic taste, tremor, try mouth, insomnia and allergic reactions [4].

Given the great costs to all parties involved of unmanaged pain, physicians should be aware of alternative pain medications to opioids, especially in cases where opioids are not fully effective. The use of this medication should be trialed before it is started for long-term use. Finally, use of IV lidocaine can cause serious side effects which should be recognized and managed appropriately. Overall, IV lidocaine is a under used pain medication and an effective alternative to opioids for some patients.

6. Learning Points/Take Home Messages

  1. Intravenous lidocaine should be considered as a pain management alternative to opioids.
  2. A trial of lidocaine should be performed to test pain response.
  3. Serious side effects including sedation, seizures and arrhythmias should be monitored.

References

  1. Institute of Medicine. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. Washington, DC: The National Academies Press (2011).
  2. Daykin H. The efficacy and safety of intravenous lidocaine for analgesia in the older adult: a literature review. Br J Pain 11 (2017): 23-31.
  3. Bartlett EE, Hutaserani Q. Lidocaine (xylocaine) for the relief of postoperative pain. J Am Med Womens Assoc 17 (1962): 809-815.
  4. Kosharskyy B, Almonte W, Shaparin N, et al. Intravenous infusions in chronic pain management. Pain Physician 16 (2013): 231-249.
  5. Yousefshahi F, Predescu O, Francisco asenjo J. The Efficacy of Systemic Lidocaine in the Management of Chronic Pain: A Literature Review. Anesth Pain Med 7 (2017): e44732.
  6. Petersen P, Kastrup J, Zeeberg I, et al. Chronic pain treatment with intravenous lidocaine. Neurol Res 8 (1986): 189-190.
  7. Terkawi AS, Sharma S, Durieux ME, et al. Perioperative lidocaine infusion reduces the incidence of post-mastectomy chronic pain: a double-blind, placebo-controlled randomized trial. Pain Physician 18 (2015): E139-E146.
  8. Sharma S, Rajagopal MR, Palat G, et al. A phase II pilot study to evaluate use of intravenous lidocaine for opioid-refractory pain in cancer patients. J Pain Symptom Manage 37 (2009): 85-93.

© 2016-2024, Copyrights Fortune Journals. All Rights Reserved